Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $19.00

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $19.00.

ENTA has been the subject of several recent analyst reports. JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, August 6th. Finally, Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $11.30 on Tuesday. The business’s 50-day moving average is $13.28 and its two-hundred day moving average is $13.64. Enanta Pharmaceuticals has a 12 month low of $8.08 and a 12 month high of $17.80. The firm has a market capitalization of $239.32 million, a PE ratio of -1.81 and a beta of 0.59.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.36. The company had revenue of $17.97 million during the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company’s revenue was down 4.9% on a year-over-year basis. During the same period last year, the firm earned ($1.27) earnings per share. Equities analysts anticipate that Enanta Pharmaceuticals will post -5.3 EPS for the current year.

Insider Buying and Selling

In related news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Scott T. Rottinghaus sold 4,299 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $15.07, for a total value of $64,785.93. Following the completion of the transaction, the insider now owns 23,988 shares of the company’s stock, valued at $361,499.16. The disclosure for this sale can be found here. Insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ENTA. Quest Partners LLC bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $146,000. Pennant Investors LP bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $330,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $118,000. Vanguard Group Inc. raised its holdings in shares of Enanta Pharmaceuticals by 7.5% during the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after buying an additional 134,292 shares during the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 1.3% during the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after buying an additional 10,952 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.